Aurinia Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AUPH and other ETFs, options, and stocks.

About AUPH

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada. 

CEO
Kevin C. Tang
CEOKevin C. Tang
Employees
128
Employees128
Headquarters
Edmonton, Alberta
HeadquartersEdmonton, Alberta
Founded
1993
Founded1993
Employees
128
Employees128

AUPH Key Statistics

Market cap
2.21B
Market cap2.21B
Price-Earnings ratio
7.08
Price-Earnings ratio7.08
Dividend yield
—
Dividend yield—
Average volume
1.03M
Average volume1.03M
High today
$16.57
High today$16.57
Low today
$16.16
Low today$16.16
Open price
$16.25
Open price$16.25
Volume
1.28M
Volume1.28M
52 Week high
$19.25
52 Week high$19.25
52 Week low
$13.52
52 Week low$13.52

Stock Snapshot

The current Aurinia Pharmaceuticals(AUPH) stock price is $16.46, with a market capitalization of 2.21B. The stock trades at a price-to-earnings (P/E) ratio of 7.08.

On 2026-11-07, Aurinia Pharmaceuticals(AUPH) stock moved within a range of $16.16 to $16.57. With shares now at $16.46, the stock is trading +1.9% above its intraday low and -0.7% below the session's peak.

Trading volume for Aurinia Pharmaceuticals(AUPH) stock has reached 1.28M, versus its average volume of 1.03M.

The stock's 52-week range extends from a low of $13.52 to a high of $19.25.

The stock's 52-week range extends from a low of $13.52 to a high of $19.25.

AUPH News

Simply Wall St 5d
Raised Revenue Outlook Could Be A Game Changer For Aurinia Pharmaceuticals - Simply Wall St

...

Raised Revenue Outlook Could Be A Game Changer For Aurinia Pharmaceuticals - Simply Wall St
Simply Wall St 6d
Aurinia Pharmaceuticals Stock Price Slips After Q3 Earnings Strength

Aurinia Pharmaceuticals came into this Q3 2026 report with a reputation for eye catching profitability and a stock priced as if that might not last. The latest...

Analyst ratings

67%

of 6 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

People also own

Based on the portfolios of people who own AUPH. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.